Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
EOLS Evolus	$9.27 +0.7%	$9.97	$8.67 ▼ $17.82	$597.69M	0.97	756,750 shs	424,231 shs
IOVA Iovance Biotherapeutics	$1.75 +0.2%	$2.15	$1.64 ▼ $12.51	$584.38M	0.85	9.02 million shs	4.64 million shs
MOLN Molecular Partners	$3.72 +0.3%	$3.85	$3.36 ▼ $12.22	$151.81M	1.1	14,810 shs	638 shs
TNGX Tango Therapeutics	$5.69 +0.7%	$3.16	$1.03 ▼ $12.02	$617.85M	1.63	1.59 million shs	620,177 shs

10 Stocks Set to Soar in Summer 2025

Enter your email address and we'll send you MarketBeat's list of ten stocks that are set to soar in Summer 2025, despite the threat of tariffs and other economic uncertainty. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
EOLS Evolus	0.00%	+1.42%	-5.41%	-13.28%	-15.65%
IOVA Iovance Biotherapeutics	0.00%	+3.79%	-4.15%	-41.53%	-76.27%
MOLN Molecular Partners	0.00%	+0.68%	+1.92%	+4.20%	-43.81%
TNGX Tango Therapeutics	0.00%	+13.57%	+74.01%	+348.03%	-31.77%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
EOLS Evolus	3.6079 of 5 stars	3.5	0.0	3.5	0.6	3.3	0.6
IOVA Iovance Biotherapeutics	4.7089 of 5 stars	4.3	1.0	4.2	1.7	4.2	1.3
MOLN Molecular Partners	2.9844 of 5 stars	3.8	5.0	0.0	1.9	0.0	0.6
TNGX Tango Therapeutics	2.1813 of 5 stars	3.5	2.0	0.0	2.6	1.7	0.0

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
EOLS Evolus	3.00	Buy	$23.75	156.20% Upside
IOVA Iovance Biotherapeutics	2.50	Moderate Buy	$12.22	596.82% Upside
MOLN Molecular Partners	3.50	Strong Buy	$12.00	222.58% Upside
TNGX Tango Therapeutics	3.00	Buy	$12.20	114.41% Upside

Current Analyst Ratings Breakdown

Latest MOLN, EOLS, TNGX, and IOVA Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
5/16/2025	IOVA Iovance Biotherapeutics	UBS Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Buy ➝ Neutral	$17.00 ➝ $2.00
5/12/2025	IOVA Iovance Biotherapeutics	The Goldman Sachs Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$16.00 ➝ $8.00
5/12/2025	IOVA Iovance Biotherapeutics	Mizuho Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Outperform ➝ Outperform	$30.00 ➝ $10.00
5/12/2025	IOVA Iovance Biotherapeutics	Barclays Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Overweight ➝ Overweight	$5.00 ➝ $4.00
5/12/2025	IOVA Iovance Biotherapeutics	Truist Financial Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Buy ➝ Hold
5/9/2025	IOVA Iovance Biotherapeutics	Baird R W Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Strong-Buy ➝ Hold
5/9/2025	IOVA Iovance Biotherapeutics	JMP Securities Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Market Outperform ➝ Market Perform
5/9/2025	IOVA Iovance Biotherapeutics	Chardan Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$30.00 ➝ $25.00
5/9/2025	IOVA Iovance Biotherapeutics	Citizens Jmp Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Outperform ➝ Market Perform
5/9/2025	IOVA Iovance Biotherapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$32.00 ➝ $20.00
5/8/2025	EOLS Evolus	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$22.00 ➝ $22.00

(Data available from 7/5/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
EOLS Evolus	$266.27M	2.24	N/A	N/A	$0.09 per share	103.00
IOVA Iovance Biotherapeutics	$164.07M	3.57	N/A	N/A	$2.33 per share	0.75
MOLN Molecular Partners	$5.65M	26.59	N/A	N/A	$3.99 per share	0.93
TNGX Tango Therapeutics	$42.07M	14.66	N/A	N/A	$1.86 per share	3.06

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
EOLS Evolus	-$50.42M	-$0.89	N/A	N/A	N/A	-20.40%	-759.04%	-20.14%	7/30/2025 (Estimated)
IOVA Iovance Biotherapeutics	-$372.18M	-$1.24	N/A	N/A	N/A	-176.49%	-49.71%	-39.18%	8/6/2025 (Estimated)
MOLN Molecular Partners	-$61.39M	-$1.92	0.00	N/A	N/A	N/A	-42.20%	-38.12%	8/25/2025 (Estimated)
TNGX Tango Therapeutics	-$130.30M	-$1.22	0.00	N/A	N/A	-322.67%	-62.75%	-39.94%	8/6/2025 (Estimated)

Latest MOLN, EOLS, TNGX, and IOVA Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
7/30/2025	Q2 2025	EOLS Evolus	-$0.09	N/A	N/A	N/A	$82.18 million	N/A
5/15/2025	Q1 2025	MOLN Molecular Partners	-$0.3855	-$0.50	-$0.1145	-$0.50	N/A	N/A
5/12/2025	Q1 2025	TNGX Tango Therapeutics	-$0.34	-$0.36	-$0.02	-$0.36	$6.73 million	$5.39 million
5/8/2025	Q1 2025	IOVA Iovance Biotherapeutics	-$0.25	-$0.36	-$0.11	-$0.36	$83.40 million	$49.32 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
EOLS Evolus	N/A	N/A	N/A	N/A	N/A
IOVA Iovance Biotherapeutics	N/A	N/A	N/A	N/A	N/A
MOLN Molecular Partners	N/A	N/A	N/A	N/A	N/A
TNGX Tango Therapeutics	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
EOLS Evolus	22.00	2.34	2.16
IOVA Iovance Biotherapeutics	N/A	4.18	3.64
MOLN Molecular Partners	N/A	15.28	15.28
TNGX Tango Therapeutics	N/A	6.26	6.26

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
EOLS Evolus	90.69%
IOVA Iovance Biotherapeutics	77.03%
MOLN Molecular Partners	26.55%
TNGX Tango Therapeutics	78.99%

Insider Ownership

Company	Insider Ownership
EOLS Evolus	5.90%
IOVA Iovance Biotherapeutics	10.30%
MOLN Molecular Partners	5.93%
TNGX Tango Therapeutics	7.50%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
EOLS Evolus	170	64.48 million	60.67 million	Optionable
IOVA Iovance Biotherapeutics	500	333.93 million	299.54 million	Optionable
MOLN Molecular Partners	180	40.38 million	37.98 million	Not Optionable
TNGX Tango Therapeutics	90	108.39 million	100.26 million	Optionable

MOLN, EOLS, TNGX, and IOVA Headlines

Recent News About These Companies

HC Wainwright Issues Positive Estimate for TNGX Earnings

July 2 at 7:41 AM | marketbeat.com

Tango Therapeutics, Inc. (NASDAQ:TNGX) Receives $12.20 Consensus Target Price from Analysts

July 1, 2025 | americanbankingnews.com

Tango Therapeutics doses first patient in cancer drug combo trial

June 29, 2025 | uk.investing.com

Tango Therapeutics (NASDAQ:TNGX) Trading 6.5% Higher - Here's What Happened

June 29, 2025 | americanbankingnews.com

Tango Therapeutics, Inc. (NASDAQ:TNGX) Receives Average Rating of "Buy" from Analysts

June 28, 2025 | marketbeat.com

Tango Therapeutics Shares Climb After First Patient Dosed in Pancreatic, Lung Cancer Trial

June 27, 2025 | marketwatch.com

Tango Therapeutics (NASDAQ:TNGX) Trading Up 6.5% - Should You Buy?

June 27, 2025 | marketbeat.com

Tango Therapeutics Announces First Patient Dosed in Phase 1/2 Trial of TNG462 plus Revolution Medicines' Daraxonrasib or Zoldonrasib in Patients with RAS-Mutant MTAP-deleted Pancreatic or Lung Cancer

June 27, 2025 | globenewswire.com

Tango Therapeutics (NASDAQ:TNGX) Shares Down 8.3% - Should You Sell?

June 25, 2025 | marketbeat.com

Tango Therapeutics (TNGX) Moves 7.5% Higher: Will This Strength Last? - Nasdaq

June 25, 2025 | nasdaq.com

Exchange Traded Concepts LLC Purchases 47,901 Shares of Tango Therapeutics, Inc. (NASDAQ:TNGX)

June 25, 2025 | marketbeat.com

Tango Therapeutics (TNGX) Moves 7.5% Higher: Will This Strength Last?

June 23, 2025 | zacks.com

Tango Therapeutics (NASDAQ:TNGX) Shares Up 4.7% - What's Next?

June 17, 2025 | marketbeat.com

Tango Therapeutics’ SWOT analysis: stock poised for growth amid clinical trials

June 16, 2025 | investing.com

Tango Therapeutics (NASDAQ:TNGX) Shares Down 7.4% - Here's What Happened

June 13, 2025 | marketbeat.com

Tango Therapeutics (NASDAQ:TNGX) Shares Gap Down - Time to Sell?

June 12, 2025 | marketbeat.com

B. Riley Expects Higher Earnings for Tango Therapeutics

June 12, 2025 | marketbeat.com

Cantor Fitzgerald Predicts TNGX FY2026 Earnings

June 11, 2025 | marketbeat.com

Q2 Earnings Forecast for TNGX Issued By B. Riley

June 11, 2025 | marketbeat.com

Tango Therapeutics (NASDAQ:TNGX) Trading Up 11.8% - Should You Buy?

June 10, 2025 | marketbeat.com

Tango Therapeutics, Inc. (NASDAQ:TNGX) Stock Holdings Increased by Bank of America Corp DE

June 9, 2025 | marketbeat.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

MOLN, EOLS, TNGX, and IOVA Company Descriptions

Evolus NASDAQ:EOLS

$9.27 +0.06 (+0.65%)

As of 07/3/2025 02:38 PM Eastern

Evolus, Inc., a performance beauty company, focuses on delivering products in the cash-pay aesthetic market in the United States, Canada, and Europe. The company offers Jeuveau, a proprietary 900 kilodalton purified botulinum toxin type A formulation for the temporary improvement in the appearance of moderate to severe glabellar lines in adults. It also provides dermal filler products under the Estyme and Evolysse names. The company was incorporated in 2012 and is headquartered in Newport Beach, California.

Iovance Biotherapeutics NASDAQ:IOVA

$1.75 +0.00 (+0.23%)

Closing price 07/3/2025 03:58 PM Eastern

Extended Trading

$1.76 +0.00 (+0.11%)

As of 07/3/2025 04:58 PM Eastern

Iovance Biotherapeutics, Inc., a commercial-stage biotechnology company, develops and commercializes cell therapies using autologous tumor infiltrating lymphocyte for the treatment of metastatic melanoma and other solid tumor cancers in the United States. The company offers Amtagvi, a tumor-derived autologous T cell immunotherapy used to treat adult patients with unresectable or metastatic melanoma; and Proleukin, an interleukin-2 product for the treatment of patients with metastatic renal cell carcinoma. It also develops lifileucel in combination with pembrolizumab to treat frontline advanced melanoma patients; LN-145 for the treatment of non-small cell lung cancer (NSCLC) and solid tumor cancers; IOV-4001, which is in Phase 1/2 IOV-GM1-201 clinical trial, for the treatment of NSCLC; and lifileucel for gynecological cancers. The company has collaborations and licensing agreements with WuXi Advanced Therapies, Inc.; National Institutes of Health; the National Cancer Institute; H. Lee Moffitt Cancer Center; The University of Texas M.D. Anderson Cancer Center; Cellectis S.A.; Novartis Pharma AG; and Boehringer Ingelheim Biopharmaceuticals GmbH. The company was formerly known as Lion Biotechnologies, Inc. and changed its name to Iovance Biotherapeutics, Inc. in June 2017. Iovance Biotherapeutics, Inc. was incorporated in 2007 and is headquartered in San Carlos, California.

Molecular Partners NASDAQ:MOLN

$3.72 +0.01 (+0.27%)

As of 07/3/2025 01:04 PM Eastern

Molecular Partners AG, a clinical-stage biotechnology company, develops designed ankyrin repeat proteins therapeutics for the treatment of oncology and virology diseases in Switzerland. The company develops MP0317, a CD40 agonist designed to activate immune cells within the tumor microenvironment by anchoring to fibroblast activation protein that is in Phase I clinical trial; and MP0533, a novel tetra-specific T cell-engaging DARPin for acute myeloid leukemia. It also develops Switch-DARPin platform, a multispecific cKIT x CD16a x CD47 Switch-DARPin program for targeted and conditional immune cell activation; and Radio-DARPin Therapy (RDT) platform, a delivery system for effective and selective delivery of radioactive payloads to solid tumors. It has license and research collaboration agreements with Novartis Pharma AG to develop DARPin-conjugated radioligand therapies; and collaboration agreement with Orano Med SAS to develop novel Radio-DARPin therapeutics. Molecular Partners AG was incorporated in 2004 and is headquartered in Schlieren, Switzerland.

Tango Therapeutics NASDAQ:TNGX

$5.69 +0.04 (+0.71%)

Closing price 07/3/2025 03:56 PM Eastern

Extended Trading

$5.69 0.00 (0.00%)

As of 07/3/2025 04:26 PM Eastern

Tango Therapeutics, Inc., a biotechnology company, discovers and develops drugs for the treatment of cancer. Its lead program is TNG908, a synthetic lethal small molecule inhibitor of protein arginine methyltransferase 5 that is being developed as a treatment for cancers with methylthioadenosine phosphorylase deletions. The company develops TNG462, an oral small molecule methylthioadenosine-cooperative inhibitor for the treatment for cancers with methylthioadenosine phosphorylase deletions; TNG260, a co-repressor of repressor element-1 silencing transcription -selective inhibitor; TNG348, an ubiquitin-specific protease 1 inhibitor to treat patients with BRCA1 or BRCA2-mutant cancers; and Target 3 for STK11-mutant cancers. It has a strategic collaboration with Gilead Sciences, Inc. for the discovery, development, and commercialization of a pipeline of therapies for patients with cancer. Tango Therapeutics, Inc. was founded in 2017 and is headquartered in Boston, Massachusetts.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time